Is Psychedelic-Mediated Therapy a Possibility or Just a Dream? Turning Clinical Success Into Real-World Practice
This Briefing is brought to you by AHLA’s Behavioral Health Practice Group.
- May 10, 2022
- Kimberly Chew , Husch Blackwell LLP
- Karen Luong , Husch Blackwell LLP
- Seth Mailhot , Husch Blackwell LLP
The development of psychedelic drugs to be used in conjunction with traditional therapies is gaining more media coverage and momentum by the day. Clinical trials, permissive legislation, and scientific research are converging to legitimize these once-stigmatized substances, prompting companies to address this new and rapidly growing body of research. Investors, too, are paying close attention, looking to back innovators whose therapies can make the leap from clinical trial success to something clinicians can work with in the real world. This article explores some of the emerging regulatory, legal, and practical challenges companies are facing.
ARTICLE TAGS
You must be logged in to access this content.